BioMarin Pharmaceuticals BMRN Net Income
Net Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's net income?
- BioMarin Pharmaceuticals (BMRN) reported net income of $105.53M in Q1 2026.
- How has BioMarin Pharmaceuticals's net income changed year-over-year?
- BioMarin Pharmaceuticals's net income decreased by 43.2% year-over-year, from $185.69M to $105.53M.
- What is the long-term trend for BioMarin Pharmaceuticals's net income?
- Over 3 years (2021 to 2024), BioMarin Pharmaceuticals's net income has grown at a 88.2% compound annual growth rate (CAGR), from -$64.08M to $426.86M.
- What does net income mean?
- The company's bottom-line profit after all expenses.
- How do you interpret net income?
- An increase indicates higher profitability and potential for reinvestment or shareholder returns.
- How does net income compare across companies?
- Standard across all public companies; peers in biotech often show volatility due to R&D cycles.